SanegeneBio Signs Major Global RNAi Licensing Deal with Genentech for Groundbreaking Therapies SanegeneBio has entered into a significant global partnership with Genentech to develop RNAi therapeutics, receiving $200 million upfront and potential earnings up to $1.5 billion.

SanegeneBio Signs Major Global RNAi Licensing Deal with Genentech for Groundbreaking Therapies #United_States #Boston #Genentech #RNAi_Therapeutics #SanegeneBio

Funding Raises: #Exein €100M ($117M) Series C+; #D2Bio $108M Series B; #ProfluentBio $106M Series B; #Antihesis $105M Series A; #OTRTherapeutics $100M Series A; #SanegeneBio $100M Series B; #HevenAeroTech $100M Series B

Mergers: #AlphaVest & #AMC

SanegeneBio raises $110m for RNAi, plus other financings Biotech financings this week include SanegeneBio's Lilly-backed $110m Series B, with Sidera, D3 Bio, BlossomHill, and Prolynx also raising new funds.

#RNAinterference drug developer #SanegeneBio leads our round-up of this week's #biotechfinancings, with a $110 million Series B backed by recent partner #EliLilly.

pharmaphorum.com/news/sanegen...

Innovent and SanegeneBio Share Promising Phase 1 Data for IBI3016 at AHA 2025 Innovent and SanegeneBio unveil Phase 1 clinical data for IBI3016 at AHA 2025, showcasing its potential to treat hypertension effectively.

Innovent and SanegeneBio Share Promising Phase 1 Data for IBI3016 at AHA 2025 #China #Suzhou #Innovent #SanegeneBio #IBI3016

SanegeneBio and Eli Lilly Unite in Groundbreaking RNAi Research Collaboration SanegeneBio partners with Eli Lilly to develop innovative RNAi therapeutics targeting metabolic diseases, leveraging advanced LEAD™ technology.

SanegeneBio and Eli Lilly Unite in Groundbreaking RNAi Research Collaboration #USA #Boston #Lilly #RNAi #SanegeneBio